bridge biotec, thinking beyond


Dr. Mike Davies and his team are focused on delivering more safe and effective peptide medecines that will change the way we currently treat serious inflammatory diseases. We are seeking further investment and with tax efficient benefits available to UK investors, we can be generating income within 3 years!

About Bridge Biotec

The Bridge Biotec team are focused on new, safer and more effective treatments for serious inflammatory diseases.

Bridge Biotec is an ambitious company aiming to be revenue generating within 3 years, by taking the lead project to regulatory approval for clinical trials (IND/CTA), or 5 years after clinical proof of concept with our lead compound. This could be via out-licencing or trade sale, or by any suitable route.

We have licenced two very important components that we plan to combine to form a range of therapies aimed at treating serious inflammatory diseases:

  • Highly potent and highly specific novel peptide (“small protein”) anti-inflammatory therapeutics

  • Safe, nanoparticle delivery polmer, that will take the peptides into human cells and switch off inflammation

By combining these two important components to form its lead compound JEL3108, we will create a new medicine to more safely and effectively treat life threatening and disabling inflammatory diseases.

Bridge is currently seeking a total of $12,000,000 investment over the next 3 years, to drive the lead compound through to regulatory approval of clinical trials (IND/CTA). Read more investment detail here.

Background and history of Bridge Biotec

Bridge was incorporated in late 2016 to reserve the name. In 2017 Bridge gained exclusive world-wide licences to develop Astra-Zeneca's peptide compounds and a clinically safe nano-particle delivery technology. We will take this combination from preclinical research to de-risked human clinical proof of concept trials, over the next 5 years, by employing cutting-edge adaptive clinical trial designs to expedite clinical trial delivery. In this way, Bridge aims to avoid much of the late stage efficacy failures experienced by large pharma companies.



investment opportunity

a 106 billion dollar market

donate to assist our research

If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.


talk to bridge biotec about investing in our work

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.


youtube bridge biotecbridge biotec facebookbridge biotec twitterbridge biotec linkedin


UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

©2018 Bridge Biotec Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
SK10 4TG